OregonTherapeutics
Laboratoire
📍 Paris, 75017
OregonTherapeutics is developing XCE853 : Disruptive targeted therapy "First in class" & "Best in class" in oncology. XCE853 is based on an innovative and unique mechanism of action : Inhibition of protein disulfide isomerase. OregonTherapeutics first objective is to bring XCE853 into clinical trial (phase 1) for the treatment of cancer within 2 years. Based on the scientific rationale, the priority indication is advanced pancreatic cancer. Potential additional indications are ovarian, livers, and head & neck cancers.
À propos
Localisation: Paris, 75017
🔒 Coordonnées (Abonnement payant requis)
Pour accéder aux coordonnées complètes (adresse, téléphone, email) et aux contacts de ce prestataire, passez à un compte payant.
Actions
Informations
Catégorie:
Laboratoire